CAPRICOR THERAPEUTICS INC. - COMMON STOCK

Capricor Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial of Novel Exosome-Based Vaccine

18 8 2025 06:00:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

11 8 2025 13:05:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA

08 8 2025 05:30:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics to Present Second Quarter 2025 Financial Results and Recent Corporate Update on August 13

06 8 2025 06:00:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Review Latest Developments in the Deramiocel Program for the Treatment of Duchenne Muscular Dystrophy

28 7 2025 06:00:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy

11 7 2025 03:30:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy

24 6 2025 06:00:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy

20 6 2025 06:25:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics Announces Orphan Drug Designation for Becker Muscular Dystrophy and Regulatory Progress for Duchenne Muscular Dystrophy Program

17 6 2025 06:00:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics Announces Key Regulatory Updates for its Duchenne Muscular Dystrophy Program

11 6 2025 06:25:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

13 5 2025 13:05:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics Appoints Michael Binks, M.D. as Chief Medical Officer

13 5 2025 06:00:01 提供 Nasdaq GlobeNewswire

Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13

06 5 2025 06:15:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics Announces Completion of Mid-Cycle Review Meeting with FDA on Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy

05 5 2025 05:00:01 提供 Nasdaq GlobeNewswire

Capricor Therapeutics to Present at the 2025 Piper Sandler Virtual Cardio Day

01 4 2025 06:00:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

19 3 2025 13:05:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics Announces Positive Data Demonstrating Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystrophy

17 3 2025 06:25:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics to Present Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Update on March 19

11 3 2025 06:00:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics to Present at Leerink’s Global Healthcare Conference 2025

07 3 2025 06:25:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics Announces FDA Acceptance and Priority Review of its Biologics License Application for Deramiocel to Treat Duchenne Muscular Dystrophy

04 3 2025 04:00:00 提供 Nasdaq GlobeNewswire